News Room
News Room
News Room
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions CHICAGO, June 11, 2026 - Paragon Biosciences today announced the [...]
JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome
Phase 3 data show delayed time to relapse and maintained tic improvement with investigational, first-in-class mechanism targeting dopamine pathway CHICAGO — May 26, 2026 — [...]
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late‑stage program in a high-need, specialized area of neuroscience expands Teva’s innovative medicines pipeline, aligns with commercial strengths and [...]
First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
Study opens pathway to investigational therapy for patients with Tourette syndrome who have exhausted approved treatments CHICAGO — March 9, 2026 — Emalex [...]
Biotech Innovation Update
Last year, Paragon Biosciences and its portfolio companies advanced transformative science with a singular mission: to accelerate breakthroughs that improve lives. Across [...]
Groundbreaking Achievements and Pivotal Milestones for Paragon and its Portfolio Companies
In 2024, Paragon and its portfolio companies achieved remarkable research and development progress, driving innovative solutions for patients with critical unmet needs. [...]
